Analysis of the leading-edge genes underlying the enrichment of each gene set within the BC and CRC patient datasets (Figure 7A) revealed great resemblance in both lists of top genes (7 out of the top 20 genes) involved in the 26 common activated pathways of HER2+ vs. HER2− patients, and the top 20 frequent genes in activated cellular pathways between HER2+ and HER2− CRC patients (Figure 7B). This evidence concerns the gene ERBB2 and breast cancer.